Lilly’s Taltz cleared to treat psoriatic arthritis
Lilly | December 05, 2017
US regulators have expanded the scope of Eli Lilly’s plaque psoriasis drug Taltz to include the treatment patients with psoriatic arthritis. Taltz (ixekizumab) is an antibody that binds to interleukin-17A, a protein that causes inflammation and plays a role in the development of these conditions. The drug is administered as an injection, either alone or in combination with a conventional disease-modifying antirheumatic drug such as methotrexate.